BUILDING A BETTER FUTURE THROUGH CONVERGENCE
was established in 2020, and has since played a key role in R&D management and creation of new future value.
The Bio/Healthcare Institute is focusing its efforts on the development of technology for the diagnosis and treatment of disease.
Especially, we are actively investing in proteomics analysis R&D to overcome the limitations of existing genomics-based technologies for the discovery of new biomarkers and treatment targets.
Internalizing core technologies of global affiliates and creating new demand in the rapidly growing diagnostics market
Overcoming the limitations of existing genomics-based technologies through proteomics R&D to discover new biomarkers and treatment targets
Translational medical research to apply laboratory-level basic science research to actual clinical settings
ARK Diagnostics’ R&D Center, located in Fremont, USA, is leading the development of IVD immunoassays for therapeutic drug monitoring (TDM), urine drug testing (UDT) and veterinary medicine. They hold and have applied for over 50 patents, and are operating a wide range of new product pipelines.
Immunodiagnostics, specialty diagnostics & veterinary diagnostics reagents
In 2018, Israel’s PixCell Medical Technologies began the commercialization of the HemoScreen™, a Point-of-Care (POC) hematology analyzer that can automatically perform blood cell analysis based on digital pathology through utilization of microfluidic technology, and are currently proceeding with mass production.
Imaging technology-based POC hematology analyzer
GeneChem’s R&D Center succeeded in the development of a “One Pot Platform” method for sialyllactose, an oligosaccharide component of breast milk, and is establishing mass production facilities for domestic and international commercialization. In addition, they are doing their best to develop pharmaceuticals for the treatment of various muscle-related diseases.
Functional glycosylated materials and products
Genic established a corporate R&D center in Pangyo, and is continuously performing research on human skin and absorption of active ingredients to develop products that are safe and have excellent efficacy and effectiveness. They are carrying out various research protects that can create new beauty trends, including research on masking technology for skincare formulations, as well as research on formulations and raw materials for hydrogel, cataplasma and film cosmetics. Genic possesses over 200 domestic and international patents.
Formulations and prescriptions for all types of skincare products
Roswell ME, located in San Diego, USA, demonstrated the world’s first commercially viable Molecular Electronics (ME) Chip™, a biosensor based on the CMOS process, and is developing a next-generation platform in the fields of genome analysis, environmental sensors, and in vitro diagnostics. Roswell ME’s next-generation platform is expected to bring disruptive innovation to the field of analysis/diagnostics.
Biosensor
